A Study of Imlunestrant, Investigator s Choice of Endocrine Therapy, and Imlunestrant plus

To determine if 3-year recurrence-free survival (RFS) is greater than 92% among clinical stages II or IIIa patients with HER2-positive breast cancer.

Have you been diagnosed with colon cancer? If so, you may be able to take part in a research study looking to find out what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer and if this approach is better or worse than the usual approach for your colon cancer.

We are looking for women between the ages of 18-45 to join a national health study to help us understand the impact of HIV on women's lives and bodies. Both women living with HIV and women without HIV are invited to take part.

Have you been recently diagnosed with Acute Myeloid Leukemia or Myelodysplastic Syndromes? If you are 60 years or older and you are scheduled to receive treatment with hypomethylating agents and Venetoclax, you and your care partner may be able to take part in a research study. In this study, we want to understand nutrition, eating, and mealtimes for people with these cancers. Compensation provided.

Do you have uterine leiomyosarcoma that has grown after initial treatment with two prior forms of chemotherapy and cannot be removed by surgery? if so you may be able to take part in a research study to find out if the combination of olaparib and temozolomide is better, worse or the same than the usual approach for advanced uterine leiomyosarcoma.

The purpose of this study is to learn more about how an investigational drug (tarlatamab) works in people with extensive-stage small cell lung cancer. In this study, we want to learn more about its safety and tolerability (effects good or bad) when used in combination with one of two other drugs (atezolizumab or durvalumab). We also want to learn more about the combination of the study drug with either atezolizumab or durvalumab and carboplatin and etopopside.

We are looking for people who are between the ages of 30-70 to join a national health study to help us better understand the impact of chronic health conditions on people living with HIV. Both people living with HIV and people without HIV are invited to take part.

Atrasentan is an investigational drug. That means it has not yet been approved by the FDA as a medicine. Researchers want to find out if taking atrasentan along with a drug called an SGLT2 inhibitor is safe and helps people with IgA nephropathy.

To determine optimal content and design features of mHealth apps for smoking cessation that are most preferred by Black and African American adults who smoke or use other tobacco products.